SitesBLAST

C344 (≠ G437) mutation to S: Small decrease in proline uptake activity. Confers resistance to N-ethylmaleimide. Exhibits low Na(+)-dependent proline binding.
C349 (≠ I442) mutation to S: Does not affect proline uptake activity. Sensitive to N-ethylmaleimide. Na(+)-dependent proline binding activity is similar to wild-type carrier.
R376 (= R469) mutation R->E,Q: No change in activity.; mutation to K: Loss of activity.

Sites not aligning to the query:

257 R→C: Sodium-independent binding affinity for proline.
281 C→S: Does not affect proline uptake activity. Confers resistance to N-ethylmaleimide. Na(+)-dependent proline binding activity is similar to wild-type carrier.

Q92911 Sodium/iodide cotransporter; Na(+)/I(-) cotransporter; Natrium iodide transporter; Sodium-iodide symporter; Na(+)/I(-) symporter; Solute carrier family 5 member 5 from Homo sapiens (Human) (see 3 papers)
26% identity, 29% coverage: 15:191/605 of query aligns to 24:204/643 of Q92911

query
sites
Q92911

F

L

L

L

L

V

Y

S

I

T

G

G

I

I

A

G

V

L

W

W

-

V

-

G

-

L

A

A

R

R

A

G

G

G

-

Q

-

R

S

S

T

A

K

E

E

D

F

F

Y

F

V

T

A

G

G

G

G

R

V

L

H

A

P

A

I

L

A

P

N

V

G

G

M

L

A

S

T

L

A

S

A

A

D

S

W

F

M

M

S

S

A

A

A

-

S

-

F

-

I

V

S

Q

L

V

A

L

G

G

L

V

I

P

S

S

F

E

I

A

G

Y

R

R

D

Y

G

G

S

L

A

K

Y

F

L

L

-

W

-

M

-

C

M

L

G

G

W

Q

T

L

G

L

G

N

Y

S

V

V

L

L

L

T

A
|
A

M

L

L

L

L

F

A

M

P

P

Y

V

L

F

R

Y

K

R

F

L

G

G

K

L

F

T

T

S

V

T

P

Y

D

E

F

Y

V

L

G

E

D

M

R

R

Y

F

E

-

S

S

N

R

T

A

A

V

R

R

I

L

I

C

G

G

V

T

A

L

C

Q

T

Y

I

I

I

V

I

A

S

T

F

M

T

L

Y

Y

V

T

A

G

G

I

Q

V

M

I

R

Y

G

A

V

P

G

A

I

L

V

I

F

L

S

N

R

Q

Y

V

L

T

H

G

V

L

D

D

I

I

N

W

T

A

G

S

V

L

I

L

L

S

G

T

M

G

A

I

I

I

V

C

F

T

F

F

Y

Y

A

T

V

A

L

V

G

G

M

M

K

K

G

A

I

V

T

V

Y

W

T

T

Q

D

V

V

A

F

Q

Q

Y

V

C

V

V

V

L

M

I

L

L

S

A

G

F

F

T

W

V

V

A102 (= A88) natural variant: A -> P

Sites not aligning to the query:

226 mutation H->A,D,E,K: Significant loss of iodide transport activity but no effect on its localization to the cell membrane.
237 D→A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization.
242 Required for homodimerization; Y→A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Reduced homodimerization; when associated with A-471. Loss of iodide transport activity; when associated with F-535.
243 Required for homodimerization; T→A: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Reduced homodimerization; when associated with A-471.
471 Required for homodimerization; Q→A: No effect on localization to the cell membrane, iodide transport activity and homodimerization. Significant loss of homodimerization; when associated with A-242 or A243.
525 A→F: Loss of localization to the cell membrane, significant loss of iodide transport activity but no effect on homodimerization. Loss of iodide transport activity; when associated with A-242.
536 T → Q: requires 2 nucleotide substitutions
556 S → Q: requires 2 nucleotide substitutions

3dh4A Crystal structure of sodium/sugar symporter with bound galactose from vibrio parahaemolyticus (see paper)
31% identity, 20% coverage: 408:528/605 of query aligns to 303:426/512 of 3dh4A

query
sites
3dh4A

A

A

N

Y

P

P

E

W

I

L

A

T

Q

Q

-

F

L

L

P

P

A

V

W

G

V

V

I

K

A

G

L

V

V

V

A

F

A

A

G

A

A

L

V

A

A

A

A
|
A

A

I

L

V

S
|
S

T

S

A

L

A

A

G

S

L

M

L

L

L

N

V

S

I

T

S

A

T

T

A

I

I

F

A

T

H

M

D

D

L

I

M

Y

K

K

T

E

V

Y

I

I

S

S

P

P

N

D

I

S

T

G

D

D

K

H

Q

K

E

L

L

V

M

N

Y

V

A

G

R

R

M

T

A

A

V

V

A

A

I

L

L

I

I

I

A

A

G

C

Y

L

F

I

G

A

-

P

-

M

I

L

N

G

P

G

P

I

G

G

F

Q

V

A

A

F

Q

Q

V

Y

V

I

A
x
Q

L

E

A

Y

F

T

G

G

I

L

A

V

S

S

A

P

S

G

V

I

F

L

P

A

T

V

L

F

M

L

L

L

G

G

I

L

F

F

Y

W

T

K

R

K

M

T

N

T

T

S

Q

K

G

G

A

A

I

I

A

I

G

G

M

V

L

V

binding beta-D-galactopyranose: Q393 (≠ A495)
binding sodium ion: A326 (= A430), S329 (= S433)

Sites not aligning to the query:

binding beta-D-galactopyranose: 40, 58, 59, 62, 225, 229, 259
binding sodium ion: 36

P31639 Sodium/glucose cotransporter 2; Na(+)/glucose cotransporter 2; Low affinity sodium-glucose cotransporter; Solute carrier family 5 member 2 from Homo sapiens (Human) (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 27:209/672 of P31639

query
sites
P31639

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A

A

D

S

W

N

M

I

S

G

A

S

A

G

S

H

F

F

I

V

S

G

L

L

A

A

G

G

L

T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G
x
V

S

A

A

G

Y
x
F

L

-

M

-

G

E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G
x
V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

V95 (≠ G73) mutation to A: Strong reduction in D-glucose transporter activity. Confers partial resistance to empagliflozin inhibition.
F98 (≠ Y76) mutation to A: Slightly decreases D-glucose transporter activity. Abolishes the binding to inhibitor, empagliflozin.
V157 (≠ G134) mutation to A: Decreases D-glucose transporter activity.

Sites not aligning to the query:

283 L→M: Strong reduction in D-glucose transporter activity. Confers partial resistance to empagliflozin inhibition.
453 F→A: Slightly decreases D-glucose transporter activity. Greatly reduces the binding to inhibitor, empagliflozin.

8hg7A Structure of human sglt2-map17 complex with sotagliflozin (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 7:189/590 of 8hg7A

query
sites
8hg7A

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A
|
A

D
x
S

W
x
N

M
x
I

S
x
G

A

S

A
x
G

S
x
H

F

F

I

V

S
x
G

L
|
L

A

A

G

G

L

T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G

V

S

A

A

G

Y

F

L

-

M

-

G
x
E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G

V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyl-oxane-3,4,5-triol: N55 (≠ W53), G59 (≠ A57), H60 (≠ S58), G63 (≠ S61), L64 (= L62), E79 (≠ G79)
binding sodium ion: A53 (= A51), S54 (≠ D52), I56 (≠ M54), G57 (≠ S55)

Sites not aligning to the query:

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-methylsulfanyl-oxane-3,4,5-triol: 266, 267, 270, 271, 301, 433, 437
binding sodium ion: 369, 372, 373
binding : 579, 583, 584, 587, 588

8hdhA Structure of human sglt2-map17 complex with canagliflozin (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 7:189/586 of 8hdhA

query
sites
8hdhA

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A
|
A

D
x
S

W
x
N

M
x
I

S
x
G

A

S

A
x
G

S
x
H

F

F

I

V

S
x
G

L
|
L

A

A

G

G

L

T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G

V

S

A

A

G

Y
x
F

L

-

M

-

G
x
E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G

V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

binding (2~{S},3~{R},4~{R},5~{S},6~{R})-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methyl-phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ W53), G59 (≠ A57), H60 (≠ S58), G63 (≠ S61), L64 (= L62), F78 (≠ Y76), E79 (≠ G79)
binding sodium ion: A53 (= A51), S54 (≠ D52), I56 (≠ M54), G57 (≠ S55)

Sites not aligning to the query:

binding (2~{S},3~{R},4~{R},5~{S},6~{R})-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methyl-phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: 267, 271, 433, 434, 437, 506
binding sodium ion: 369, 372, 373
binding : 575, 579, 580, 583, 584

8hb0A Structure of human sglt2-map17 complex with ta1887 (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 7:189/586 of 8hb0A

query
sites
8hb0A

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A
|
A

D

S

W
x
N

M
x
I

S
x
G

A

S

A

G

S
x
H

F

F

I

V

S
x
G

L
|
L

A

A

G

G

L
x
T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G
x
V

S

A

A

G

Y
x
F

L

-

M

-

G
x
E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G
x
V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

binding (2R,3R,4S,5S,6R)-2-[3-[(4-cyclopropylphenyl)methyl]-4-fluoranyl-indol-1-yl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ W53), H60 (≠ S58), G63 (≠ S61), L64 (= L62), T67 (≠ L65), V75 (≠ G73), F78 (≠ Y76), E79 (≠ G79), V137 (≠ G134)
binding sodium ion: A53 (= A51), I56 (≠ M54), G57 (≠ S55)

Sites not aligning to the query:

binding (2R,3R,4S,5S,6R)-2-[3-[(4-cyclopropylphenyl)methyl]-4-fluoranyl-indol-1-yl]-6-(hydroxymethyl)oxane-3,4,5-triol: 266, 267, 271, 433, 437
binding sodium ion: 369, 372, 373
binding : 575, 576, 579, 580, 583, 584

7vsiA Structure of human sglt2-map17 complex bound with empagliflozin (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 7:189/586 of 7vsiA

query
sites
7vsiA

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A

A

D

S

W
x
N

M

I

S

G

A

S

A

G

S
x
H

F

F

I

V

S
x
G

L
|
L

A

A

G

G

L

T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G
x
V

S

A

A

G

Y
x
F

L

-

M

-

G
x
E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G

V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ W53), H60 (≠ S58), G63 (≠ S61), L64 (= L62), V75 (≠ G73), F78 (≠ Y76), E79 (≠ G79)

Sites not aligning to the query:

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: 266, 267, 270, 433, 434, 437

8hezA Structure of human sglt2-map17 complex with dapagliflozin (see paper)
25% identity, 29% coverage: 9:186/605 of query aligns to 7:189/582 of 8hezA

query
sites
8hezA

L

L

F

V

I

I

G

A

S

Y

F

F

L

L

Y

V

I

I

G

G

I

V

A

G

V

L

W

W

A

S

R

M

A

C

-

R

-

T

-

N

-

R

G

G

S

T

T

V

K

G

E

G

F

Y

Y

F

V

L

A

A

G

G

G

R

G

S

V

M

H

V

P

W

I

W

A

P

N

V

G

G

M

A

A

S

T

L

A

F

A
|
A

D

S

W
x
N

M
x
I

S
x
G

A

S

A
x
G

S
x
H

F

F

I

V

S
x
G

L
|
L

A

A

G

G

L
x
T

I

G

S

A

F

A

I

S

G

G

R

L

D

A

G

V

S

A

A

G

Y
x
F

L

-

M

-

G
x
E

W

W

T

N

G

A

G

L

Y

F

V

V

-

V

-

L

L

L

A

G

M

W

L

L

L

F

A

A

P

P

Y

V

L

Y

R

L

K

T

F

A

G

G

K

V

F

I

T

T

V

M

P

P

D

Q

F

Y

V

L

G

R

D

K

R

R

Y

F

E

G

S

G

N

R

T

R

A

I

R

R

I

L

-

Y

I

L

G

S

V

V

A

L

C

S

T

L

I

F

I

L

I

Y

S

I

F

F

T

T

Y

K

V

I

A

S

G

V

Q

D

M

M

R

F

G

S

V

G

G

A

I

V

V

F

F

I

S

Q

R

Q

Y

A

L

L

H

G

V

W

D

N

I

I

N

Y

T

A

G

S

V

V

I

I

L

A

G

L

M

L

A

G

I

I

V

T

F

M

F

I

Y

Y

A

T

V

V

L

T

G

G

M

L

K

A

G

A

I

L

T

M

Y

Y

T

T

Q

D

V

T

A

V

Q

Q

Y

T

C

F

V

V

L

I

I

L

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: N55 (≠ W53), G59 (≠ A57), H60 (≠ S58), G63 (≠ S61), L64 (= L62), T67 (≠ L65), F78 (≠ Y76), E79 (≠ G79)
binding sodium ion: A53 (= A51), I56 (≠ M54), G57 (≠ S55)

Sites not aligning to the query:

binding (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol: 266, 267, 271, 301, 433, 437
binding sodium ion: 369, 372, 373
binding : 568, 571, 572, 575, 576, 579, 580

Query Sequence

>WP_054343064.1 NCBI__GCF_001305295.1:WP_054343064.1
MSVDMLSYLFIGGSFLLYIGIAVWARAGSTKEFYVAGGGVHPIANGMATAADWMSAASFI
SLAGLISFIGRDGSAYLMGWTGGYVLLAMLLAPYLRKFGKFTVPDFVGDRYESNTARIIG
VACTIIISFTYVAGQMRGVGIVFSRYLHVDINTGVILGMAIVFFYAVLGGMKGITYTQVA
QYCVLILAFTVPAFFLSAQVTGHILPQIGLGATLETGQSVLATLDQLSMDLGFAQYTTGT
KSTIDIFCLTVALMCGTAGLPHVIVRFFTVPRVKDARTSAGYALIFIALLYTAIPGVAGF
GRVNLIQTLNGPDNAGTEYAAIPDWFKNWENAGLLAWNDRNGDGKIQYAAGSAFDSKGGK
PAFDDGADPRGEMGQRLATNALVGAEFDATKQPFANEVYVDRDIMVLANPEIAQLPAWVI
ALVAAGAVAAALSTAAGLLLVISTAIAHDLMKTVISPNITDKQELMYARMAAVVAILIAG
YFGINPPGFVAQVVALAFGIASASVFPTLMLGIFYTRMNTQGAIAGMLVGLLSTVGYMWY
FVFGGGDPADYFMGISPGGFGAVGLVLHFVVAIVVAKFTPPPSEEMQRIVADLRIPRGAG
EAHAH

Or try a new SitesBLAST search

SitesBLAST's Database

SitesBLAST's database includes (1) SwissProt entries with experimentally-supported functional features; and (2) protein structures with bound ligands, from the BioLip database.

by Morgan Price, Arkin group
Lawrence Berkeley National Laboratory